GlassScriptPhysician profile
Katharine Thomas
NPI 1588010482
$54,278.49
in general payments reported to CMS, 2019-2025
42 companies · $53K in 2025
The $53K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2021: $95.00 · 2022: $205 · 2023: $572 · 2024: $609 · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $18K · Travel and Lodging: $16K · Consulting Fee: $12K · Food and Beverage: $4,683 · Honoraria: $2,500 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,750.00 |
| Travel and Lodging | $16,425.34 |
| Consulting Fee | $12,252.00 |
| Food and Beverage | $4,683.21 |
| Honoraria | $2,500.00 |
| Education | $101.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $47,731.09 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $1,650.00 | 2025 | |
| Daiichi Sankyo INC. | $1,423.90 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $440.68 | 2023-2025 | Tagrisso, Enhertu, Imfinzi |
| Genzyme Corporation | $294.53 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $181.25 | 2024-2025 | Qinlock, Romvimza |
| Astellas Pharma US INC | $173.57 | 2021-2025 | Vyloy |
| Novocure INC. | $167.83 | 2025 | Optune Lua (Novottf-200t) |
| Regeneron Healthcare Solutions, INC. | $163.06 | 2025 | Libtayo |
| Adaptive Biotechnologies Corporation | $160.33 | 2025 | Clonoseq |
| Genentech USA, INC. | $142.31 | 2019 | |
| Glaxosmithkline, LLC. | $124.99 | 2019 | |
| Gt Medical Technologies, INC | $123.02 | 2023 | Gammatile |
| Array Biopharma INC | $113.82 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Biotech, INC. | $110.58 | 2024-2025 | Tecvayli, Talvey, Darzalex |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $105.42 | 2022 | |
| Incyte Corporation | $105.40 | 2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech, INC. | $99.22 | 2022 | |
| Abbvie INC. | $98.62 | 2023-2025 | |
| Sobi, INC | $81.95 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $56.95 | 2024-2025 | Opdivo |
| Astellas Pharma Global Development | $56.38 | 2025 | Padcev |
| Pfizer INC. | $51.42 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $47.06 | 2024-2025 | Onivyde |
| Merck Sharp & Dohme LLC | $44.54 | 2023-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $43.56 | 2025 | Iclusig, Ninlaro |
| Springworks Therapeutics, INC. | $42.06 | 2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $34.88 | 2025 | |
| Karyopharm Therapeutics INC. | $33.93 | 2024 | Xpovio |
| Lilly USA, LLC | $30.56 | 2023-2025 | Verzenio, Jaypirca |
| Seagen INC. | $30.52 | 2023 | |
| Spectrum Pharmaceuticals INC. | $27.96 | 2023 | Rolvedon |
| Kite Pharma, INC. | $26.68 | 2025 | Yescarta |
| Genmab U.S., INC. | $25.27 | 2025 | Epkinly |
| Celgene Corporation | $24.61 | 2023 | Pomalyst |
| Legend Biotech USA INC. | $23.27 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Iovance Biotherapeutics, INC. | $20.98 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $18.71 | 2025 | Brukinsa |
| Eisai INC. | $16.64 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katharine Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.